<DOC>
	<DOCNO>NCT00312832</DOCNO>
	<brief_summary>Background : Stavudine-containing regimen associate potential lipoatrophy dyslipidemia . We assess safety efficacy reduce dose stavudine compare switch tenofovir maintain standard dose stavudine . Methods : Clinically stable lipoatrophic HIV-infected patient receive antiretroviral therapy contain stavudine 40 mg bid plasma HIV RNA &lt; 200 copies/mL least 6 month randomize maintain stavudine 40 mg bid ( d4T40 arm ) , reduce 30 mg bid ( d4T30 arm ) , switch stavudine tenofovir-DF ( TDF arm ) preserve remain drug . Fasting metabolic parameter assess baseline week 4 , 12 , 24 . Mitochondrial parameter peripheral blood mononuclear cell body composition measure baseline week 24 .</brief_summary>
	<brief_title>Study Comparing Reducing Dose Stavudine Versus Switching Tenofovir HIV-Infected Patients Receiving Antiretroviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Study eligibility criterion include documented HIV infection , age 18 year old , moderate severe clinical lipoatrophy least one region upon physical examination ( 17,18 ) , viral load &lt; 200 copies/mL least 6 month prior inclusion study , stable triple antiretroviral therapy include d4T 40 mg bid least 6 preceding month , prior TDF use . Prior TDF use , viral load &gt; 200 copy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>HIV</keyword>
	<keyword>d4T</keyword>
	<keyword>TDF</keyword>
	<keyword>lipoatrophy</keyword>
	<keyword>treatment experience</keyword>
	<keyword>HIV-infection</keyword>
</DOC>